All News

The oral gepant reduced monthly migraine days as well as mean monthly use of migraine rescue medication.

ACP CRC first screening age questioned; elders over age 75 years respond better to statins; 1 drink/day ups risk for HTN; OTC lifesaver #2; plus a triple virus assay.

The ACIP was unanimous in its recommendation for routine use of nirsevimab-alip to prevent RSV LRTD in newborns and young infants during their first RSV season.

The only head-to-head trial of mRNA COVID-19 vaccine safety in older adults finds one has a slight edge over the other, which might just be enough for some patients.

A daily dose of clinical news on Patient Care you may have missed.

The end of another quarter means a new list of FDA-approved drugs for primary care. Which ones should you know about?

Statistically significant positive immune responses were observed in both vaccine-naive adults and those previously vaccinated, including for the vaccine's 8 unique serotypes.

The arrival of COVID-19 vaccines challenged many people for the first time to understand the actual public health role of vaccination. With the RSV shots, it may be round 2.

The triple assay can identify and differentiate influenza, COVID-19, and respiratory syncytial virus in approximately 2 hours and is already in use.

ACIP guidance on influenza vaccination for the 2023-2024 respiratory virus season includes updates important for primary care clinicians.

A daily dose of clinical news on Patient Care you may have missed.

Findings suggest low- to moderate-intensity statins may be more appealing as initial treatment in older persons at a higher risk for adverse events, say authors.

The American College of Physicians in the updated guidance maintains the risk/benefit ratio supports screening initiation at age 50 (vs 45) years.

His relationship with primary care physicians is one of the most important, says physiatrist DJ Kennedy, MD, and he lists the reasons in this interview.

The association between ETOH consumption and hypertension among 19 500 healthy adults was "direct and linear," a new dose-response meta-analysis found.

A daily dose of clinical news on Patient Care you may have missed.

RiVive™ nasal spray is the second nonprescription naloxone product approved by the FDA for the emergency treatment of opioid overdose.

The new policy is helping people who are taking insulin save money and helping others to afford it in the first place, says a study coauthor from the USC Sol Price School of Public Policy .